open access

Vol 89, No 5 (2021)
Research paper
Submitted: 2021-04-07
Accepted: 2021-05-03
Published online: 2021-10-13
Get Citation

On-admission versus in-hospital thromboembolism due to COVID-19 infection. What is the particular characteristic of those with early thrombotic events?

Somayeh Sadeghi12, Elaheh Keivany3, Maryam Nasirian24, Peiman Nasri54
DOI: 10.5603/ARM.a2021.0083
·
Pubmed: 34668181
·
Adv Respir Med 2021;89(5):484-492.
Affiliations
  1. Acquired Immunodeficiency Research Center, Isfahan University of Medical Sciences, Isfahan, Iran, Isfahan University of Medical Sciences, Isfahan, Iran
  2. Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran, Isfahan University of Medical Sciences, Isfahan, Iran
  3. Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran, Isfahan University of Medical Sciences, Isfahan, Iran
  4. Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non-communicable Disease, Emam Hossein Children’s Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
  5. Metabolic Liver Disease Research Center, Isfahan University of Medical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran

open access

Vol 89, No 5 (2021)
ORIGINAL PAPERS
Submitted: 2021-04-07
Accepted: 2021-05-03
Published online: 2021-10-13

Abstract

Introduction: Increasing evidence has declared a hypercoagulable state in the coronavirus 2019 infection (COVID-19), while the etiology has remained a question. For the first time, the current study has aimed to compare the contributors of thromboembolism among those whose primary manifestations of COVID-19 were thrombosis vs the patients with a thrombotic event during the period of hospitalization.
Material and methods: This case-control study has been conducted on 267 COVID-19 patients, including 59, 48, and 160 ones with an on-admission, in-hospital, and without a thrombotic event, respectively. The events were defined as deep vein thrombosis (DVT), ischemic cerebrovascular accidents (CVA), pulmonary thromboembolism (PTE), or acute myocardial infarction (AMI). The demographic, physical examination, clinical and laboratory assessments of the groups were compared.
Results: The DVT (OR: 5.18; 95% CI: 1.01–26.7), AMI (OR: 11.1; 95% CI: 2.36–52.3), and arterial thrombosis (OR: 5.93; 95% CI: 0.63–55.8) were significantly associated with an on-admission thrombosis compared to those who presented in-hospital events. Lower levels of oxygen saturation were the only significant predictor index inversely associated with on-admission thrombosis compared to those with an event during the hospital admission period.
Conclusion: PTE development was the most common in-hospital thrombotic event, whereas other thromboembolism types were remarkably more often among cases with on-admission events. Oxygen saturation was the only predictor of premature thrombosis that was inversely associated with outpatient events.

Abstract

Introduction: Increasing evidence has declared a hypercoagulable state in the coronavirus 2019 infection (COVID-19), while the etiology has remained a question. For the first time, the current study has aimed to compare the contributors of thromboembolism among those whose primary manifestations of COVID-19 were thrombosis vs the patients with a thrombotic event during the period of hospitalization.
Material and methods: This case-control study has been conducted on 267 COVID-19 patients, including 59, 48, and 160 ones with an on-admission, in-hospital, and without a thrombotic event, respectively. The events were defined as deep vein thrombosis (DVT), ischemic cerebrovascular accidents (CVA), pulmonary thromboembolism (PTE), or acute myocardial infarction (AMI). The demographic, physical examination, clinical and laboratory assessments of the groups were compared.
Results: The DVT (OR: 5.18; 95% CI: 1.01–26.7), AMI (OR: 11.1; 95% CI: 2.36–52.3), and arterial thrombosis (OR: 5.93; 95% CI: 0.63–55.8) were significantly associated with an on-admission thrombosis compared to those who presented in-hospital events. Lower levels of oxygen saturation were the only significant predictor index inversely associated with on-admission thrombosis compared to those with an event during the hospital admission period.
Conclusion: PTE development was the most common in-hospital thrombotic event, whereas other thromboembolism types were remarkably more often among cases with on-admission events. Oxygen saturation was the only predictor of premature thrombosis that was inversely associated with outpatient events.

Get Citation

Keywords

COVID-19; thrombophilia; thromboembolism; SARS-CoV-2; case-control studies

Supp./Additional Files (1)
Title page
Download
15KB
About this article
Title

On-admission versus in-hospital thromboembolism due to COVID-19 infection. What is the particular characteristic of those with early thrombotic events?

Journal

Advances in Respiratory Medicine

Issue

Vol 89, No 5 (2021)

Article type

Research paper

Pages

484-492

Published online

2021-10-13

DOI

10.5603/ARM.a2021.0083

Pubmed

34668181

Bibliographic record

Adv Respir Med 2021;89(5):484-492.

Keywords

COVID-19
thrombophilia
thromboembolism
SARS-CoV-2
case-control studies

Authors

Somayeh Sadeghi
Elaheh Keivany
Maryam Nasirian
Peiman Nasri

References (39)
  1. Guan WJ, Ni ZY, Hu Yu, et al. China Medical Treatment Expert Group for Covid-19. Clinical characteristics of Coronavirus disease 2019 in China. N Engl J Med. 2020; 382(18): 1708–1720.
  2. Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol. 2020; 75(18): 2352–2371.
  3. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13): 1239–1242.
  4. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020; 395(10234): 1417–1418.
  5. Iba T, Levy JH, Levi M, et al. Coagulopathy in COVID-19. J Thromb Haemost. 2020; 18(9): 2103–2109.
  6. Violi F, Pastori D, Cangemi R, et al. Hypercoagulation and antithrombotic treatment in Coronavirus 2019: A new challenge. Thromb Haemost. 2020; 120(6): 949–956.
  7. Nicolai L, Leunig A, Brambs S, et al. Immunothrombotic dysregulation in COVID-19 pneumonia is associated with respiratory failure and coagulopathy. Circulation. 2020; 142(12): 1176–1189.
  8. Helms J, Tacquard C, Severac F, et al. CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis). High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020; 46(6): 1089–1098.
  9. McFadyen JD, Stevens H, Peter K. The emerging threat of (micro)thrombosis in COVID-19 and its therapeutic implications. Circ Res. 2020; 127(4): 571–587.
  10. Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020; 383(2): 120–128.
  11. Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020; 18(5): 1023–1026.
  12. Cattaneo M, Bertinato EM, Birocchi S, et al. Pulmonary embolism or pulmonary thrombosis in COVID-19? Is the recommendation to use high-dose heparin for thromboprophylaxis justified? Thromb Haemost. 2020; 120(8): 1230–1232.
  13. Zhai Z, Li C, Chen Y, et al. Prevention Treatment of VTE Associated with COVID-19 Infection Consensus Statement Group. Prevention and treatment of venous thromboembolism associated with coronavirus disease 2019 infection: A consensus statement before guidelines. Thromb Haemost. 2020; 120(6): 937–948.
  14. Kruger PC, Eikelboom JW, Douketis JD, et al. Deep vein thrombosis: update on diagnosis and management. Med J Aust. 2019; 210(11): 516–524.
  15. Nagamalesh UM, Prakash VS, Naidu KC, et al. Acute pulmonary thromboembolism: Epidemiology, predictors, and long-term outcome - A single center experience. Indian Heart J. 2017; 69(2): 160–164.
  16. Ilonzo N, Rao A, Berger K, et al. Acute thrombotic events as initial presentation of patients with COVID-19 infection. J Vasc Surg Cases Innov Tech. 2020; 6(3): 381–383.
  17. Cui S, Chen S, Li X, et al. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020; 18(6): 1421–1424.
  18. Sang L, Chen S, Zheng X, et al. DVT incidence and risk factors in critically ill patients with COVID-19. J Thromb Thrombolysis. 2021; 51(1): 33–39.
  19. Mestre-Gómez B, Lorente-Ramos RM, Rogado J, et al. Infanta Leonor Thrombosis Research Group. Incidence of pulmonary embolism in non-critically ill COVID-19 patients. Predicting factors for a challenging diagnosis. J Thromb Thrombolysis. 2021; 51(1): 40–46.
  20. Chen B, Jiang C, Han B, et al. High prevalence of occult thrombosis in cases of mild/moderate COVID-19. Int J Infect Dis. 2021; 104: 77–82.
  21. Watson RA, Johnson DM, Dharia RN, et al. Anti-coagulant and anti-platelet therapy in the COVID-19 patient: a best practices quality initiative across a large health system. Hosp Pract (1995). 2020; 48(4): 169–179.
  22. Mohamed-Hussein AAR, Aly KME, Ibrahim MEAA. Should aspirin be used for prophylaxis of COVID-19-induced coagulopathy? Med Hypotheses. 2020; 144: 109975.
  23. Yang Q, Zhou X, Li Y. Antiplatelet therapy following percutaneous coronary intervention in patients complicated by COVID-19: implications from clinical features to pathological findings. Circulation. 2020; 141(22): 1736–1738.
  24. Hanff TC, Mohareb AM, Giri J, et al. Thrombosis in COVID-19. Am J Hematol. 2020; 95(12): 1578–1589.
  25. Woodard PK. Pulmonary Thromboembolism in COVID-19. Radiology. 2021; 298(2): E107–E108.
  26. Ortega-Paz L, Capodanno D, Montalescot G, et al. Coronavirus disease 2019-associated thrombosis and coagulopathy: review of the pathophysiological characteristics and implications for antithrombotic management. J Am Heart Assoc. 2021; 10(3): e019650.
  27. Zuo Yu, Yalavarthi S, Shi H, et al. Neutrophil extracellular traps in COVID-19. JCI Insight. 2020; 5(11).
  28. Petito E, Falcinelli E, Paliani U, et al. Neutrophil more than platelet activation associates with thrombotic complications in COVID-19 patients. The Journal of infectious diseases. 2020; 223(6).
  29. Srivastava S, Garg I, Bansal A, et al. COVID-19 infection and thrombosis. Clin Chim Acta. 2020; 510: 344–346.
  30. Li J, Li M, Zheng S, et al. Plasma albumin levels predict risk for nonsurvivors in critically ill patients with COVID-19. Biomark Med. 2020; 14(10): 827–837.
  31. Scialpi M, Scialpi S, Piscioli I, et al. Pulmonary thromboembolism in critical ill COVID-19 patients. Int J Infect Dis. 2020; 95: 361–362.
  32. Klok FA, Kruip MJ, van der Meer NJM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thromb Res. 2020; 191: 148–150.
  33. Longchamp A, Longchamp J, Manzocchi-Besson S, et al. Venous thromboembolism in critically Ill patients with COVID-19: Results of a screening study for deep vein thrombosis. Res Pract Thromb Haemost. 2020; 4(5): 842–847.
  34. Llitjos JF, Leclerc M, Chochois C, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost. 2020; 18(7): 1743–1746.
  35. Amin AN, Varker H, Princic N, et al. Duration of venous thromboembolism risk across a continuum in medically ill hospitalized patients. J Hosp Med. 2012; 7(3): 231–238.
  36. Darzi AJ, Repp AB, Spencer FA, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv. 2018; 2(22): 3198–3225.
  37. Gibson CM, Spyropoulos AC, Cohen AT, et al. The IMPROVEDD VTE Risk Score: Incorporation of D-dimer into the IMPROVE score to improve venous thromboembolism risk stratification. TH Open. 2017; 1(1): e56–e65.
  38. Phend C. COVID-19: anticoagulation recommended even after discharge. MedPage Today. ; 2020.
  39. Costa A, Weinstein ES, Sahoo DR, et al. How to build the plane while flying: VTE/PE thromboprophylaxis clinical guidelines for COVID-19 patients. Disaster Med Public Health Prep. 2020; 14(3): 391–405.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl